Drugs: Prices

(asked on 1st October 2020) - View Source

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps his Department has taken to respond to concerns raised by the Competition and Markets Authority on the pricing of (a) hydrocortisone tablets and (b) liothyronine tablets since 2016.


Answered by
Jo Churchill Portrait
Jo Churchill
Minister of State (Department for Work and Pensions)
This question was answered on 22nd October 2020

Concerns about potential drug pricing abuses are a matter for the Competition and Markets Authority (CMA). The CMA has several ongoing investigations into excessive prices of generic medicines. Where it has concern about the price of a generic medicine, the Department asks the CMA to investigate that price.

Reticulating Splines